Targeted Prostate Health Checks, a novel system to identify men with prostate cancer—A pilot study

Author:

Langley Stephen1ORCID,Goad Jeremy2,Bell Stephanie3,Foster Lee3,Hodges Catherine4,Laniado Marc5,Pietrasik Michele1,Rooke Alison1,Knight Matthew2ORCID,Bosonnet Edward2,Bott Simon6

Affiliation:

1. The Stokes Centre for Urology Royal Surrey Hospital NHS Foundation Trust Guildford UK

2. Medefer Ltd London UK

3. Surrey and Sussex Cancer Alliance Guildford UK

4. Surrey Primary Care Lead Surrey & Sussex Cancer Alliance Guildford UK

5. Wexham Park Hospital Slough Berkshire UK

6. Frimley Park Hospital, Frimley Health NHS Foundation Trust Frimley UK

Abstract

AbstractObjectivesThe objective of this study is to report the pilot phase of the Targeted Prostate Health Check programme that aims to identify men in the Surrey and Sussex region who have prostate cancer and who failed to be detected during the Covid era.Subjects and methodsMen aged 50 to 70, or 45 to 70 if Black or with a family history of prostate cancer, were identified from participating general practitioner (GP) records. Short message service (SMS) texts invited men to visit www.talkprostate.co.uk for information on prostate cancer and give consent to prostate‐specific antigen (PSA) checks coordinated by a third‐party virtual healthcare provider. Elevated age‐related PSA levels, or levels below age‐related thresholds but at 3 ng/mL or more, triggered referral to a rapid access urology clinic. GPs were informed of the results.ResultsFrom 1842 text messages inviting 1549 people, 544 men consented to a PSA check. From 500 phlebotomy appointments, 485 (30% of invited men) took the PSA test of whom 68 (14%) were referred with an elevated PSA. After clinical review with multiparametric magnetic resonance imaging (mp‐MRI), 22 patients underwent transperineal biopsies, and prostate cancer was detected in 18 men of whom 17 (95%) had clinically significant cancer.ConclusionOur Targeted Prostate Cancer Health Check system identifies men at risk without burdening primary care. Awareness on prostate cancer risk was raised in 1549 invited men, half of whom were further educated via the registration website. One third of invited men were checked in whom clinically significant prostate cancer was found in 3.5%.

Publisher

Wiley

Reference32 articles.

1. Surrey and Sussex Cancer Alliance. Accessed 29 September 2023.https://surreyandsussexcanceralliance.nhs.uk/

2. Medefer. Accessed 29 Sept 2023.https://medefer.com.

3. National Institute for Health and Care Excellence. NICE guideline [NG12] Suspected Cancer: recognition and referral. Accessed 29 Sept 2023.https://www.nice.org.uk/guidance/ng12/chapter/Recommendations-organised-by-site-of-cancer#urological-cancers

4. The NHS England Clinical Expert Group for prostate cancer: Guidance to support the optimal pathway for prostate cancer January 2019. Accessed 29 Sept 2023.https://prostatecanceruk.org/media/dadbsf0c/guidance-to-support-the-optimal-timed-pathway-for-prostate-cancer.pdf

5. https://www.gov.uk/government/publications/prostate-specific-antigen-testing-explanation-and-implementation/advising-well-men-about-the-psa-test-for-prostate-cancer-information-for-gps#psa-test. Accessed Sept 2023.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3